February 24, 2026 HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT BusinessWire View Article
January 13, 2026 Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT Dermatology Times View Article
January 6, 2026 Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study Globe Newswire View Article
December 2, 2025 Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer Globe Newswire View Article
October 31, 2025 Alpha TAU Medical – Bassett Healthcare in Cooperstown is home to a national clinical trial that uses a new radiation therapy for inoperable pancreatic cancer. The Daily Star View Article
September 2, 2025 Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial Globe Newswire View Article
April 28, 2025 Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals View Article
April 2, 2025 Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma View Article
February 3, 2025 Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease View Article
